Literature DB >> 15919663

Transactivation-dependent and -independent regulation of p73 stability.

Iqbal Dulloo1, Kanaga Sabapathy.   

Abstract

The tumor suppressor p53 regulates its own stability by transcriptionally activating Mdm2, Pirh2, and COP1, which target p53 for degradation. However, whether such a negative feedback mechanism exists to regulate the stability of p73, the structural and functional homologue of p53, is unclear. Unlike p53, p73 is not mutated in cancers, but its expression is significantly elevated. Thus, we have investigated the regulation of p73 turnover. Our data suggest the existence of a negative feedback mechanism for p73 degradation. p73 mutants with compromised transactivation activity are generally more stable than the full-length TAp73 form. TAp73 appears to promote its own turnover as well as that of other p73 forms, including the DeltaNp73 that lacks the amino-terminal transactivation domain, in a transactivation-dependent manner. This degradation-inducing property of TAp73 was inhibited only by p73 mutants that also inhibit the transactivation activity TAp73 but not by mutant p53, highlighting the specificity in the regulation of p73 stability. Moreover, regions in the amino and carboxyl termini of p73 confer both stabilizing and destabilizing effects on the protein, independent of its transactivation ability. Finally, we have identified the regions between amino acids 56 and 248 of p73 as being the region required for p73-mediated and for ubiquitin-mediated degradation. Taken together, the data suggest that p73 turnover is tightly regulated in a transactivation-dependent and -independent manner, resulting in the controlled expression of the various p73 forms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15919663     DOI: 10.1074/jbc.M501702200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

2.  TAp73 protein stability is controlled by histone deacetylase 1 via regulation of Hsp90 chaperone function.

Authors:  Jin Zhang; Enshun Xu; Xinbin Chen
Journal:  J Biol Chem       Date:  2013-01-29       Impact factor: 5.157

Review 3.  p53 mutations in cancer.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Nat Cell Biol       Date:  2013-01       Impact factor: 28.824

4.  NSP 5a3a: a potential novel cancer target in head and neck carcinoma.

Authors:  Luca D'agostino; Antonio Giordano
Journal:  Oncotarget       Date:  2010-10

5.  A novel dual signaling axis for NSP 5a3a induced apoptosis in head and neck carcinoma.

Authors:  Luca D'Agostino; Antonio Giordano
Journal:  Oncotarget       Date:  2011-12

Review 6.  Regulation of p73 activity by post-translational modifications.

Authors:  F Conforti; A E Sayan; R Sreekumar; B S Sayan
Journal:  Cell Death Dis       Date:  2012-03-15       Impact factor: 8.469

7.  Interplay between TAp73 Protein and Selected Activator Protein-1 (AP-1) Family Members Promotes AP-1 Target Gene Activation and Cellular Growth.

Authors:  Deepa Subramanian; Wilawan Bunjobpol; Kanaga Sabapathy
Journal:  J Biol Chem       Date:  2015-05-27       Impact factor: 5.157

8.  p53 inactivation upregulates p73 expression through E2F-1 mediated transcription.

Authors:  Chaitali Tophkhane; Shi-He Yang; Yunbo Jiang; Zhikun Ma; Dharmalingam Subramaniam; Shrikant Anant; Shingo Yogosawa; Toshiyuki Sakai; Wan-Guo Liu; Susan Edgerton; Ann Thor; Xiaohe Yang
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

9.  Cataloging and organizing p73 interactions in cell cycle arrest and apoptosis.

Authors:  Melda Tozluoğlu; Ezgi Karaca; Turkan Haliloglu; Ruth Nussinov
Journal:  Nucleic Acids Res       Date:  2008-07-26       Impact factor: 16.971

10.  A nanotechnological, molecular-modeling, and immunological approach to study the interaction of the anti-tumorigenic peptide p28 with the p53 family of proteins.

Authors:  Emilia Coppari; Tohru Yamada; Anna Rita Bizzarri; Craig W Beattie; Salvatore Cannistraro
Journal:  Int J Nanomedicine       Date:  2014-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.